This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
CSL Behring N.V.
CSL Behring N.V., a global leader in biotherapeutics, is headquartered in Belgium and operates extensively across Europe, North America, and Asia-Pacific. Founded in 1904, the company has established itself in the biotechnology industry, focusing on the development and manufacture of innovative therapies for rare and serious medical conditions. CSL Behring is renowned for its core products, including immunoglobulins, clotting factors, and albumin, which are derived from human plasma. These therapies are unique due to their high purity and efficacy, addressing critical health needs for patients with immune deficiencies and bleeding disorders. With a strong market position, CSL Behring has achieved significant milestones, including numerous regulatory approvals and a commitment to advancing patient care through research and development.
DitchCarbon Score
How does CSL Behring N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CSL Behring N.V.'s score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CSL Behring N.V., headquartered in Belgium, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of CSL Limited, which cascades its emissions data and climate commitments. As part of its corporate family, CSL Behring N.V. adheres to the sustainability initiatives and targets set by CSL Limited. CSL Limited has established various climate commitments, including participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, specific reduction targets or achievements for CSL Behring N.V. have not been detailed in the available information. The company is expected to align with the broader sustainability goals of its parent organisation, which focuses on reducing carbon emissions across its operations. As a subsidiary, CSL Behring N.V. is positioned to benefit from the climate strategies implemented by CSL Limited, although specific metrics and targets for emissions reductions have not been disclosed at this level. The absence of detailed emissions data highlights the ongoing need for transparency and commitment to climate action within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CSL Behring N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
